ScreenerHero

ECILC EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.

BIST · TR · Healthcare · Drug Manufacturers - Specialty & Generic · eis.com.tr
64.85TRY+1.25%Mkt Cap: 1.06B $P/E: —

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. The Health segment is involved…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap1.06B USD
Enterprise Value1.08B USD
Revenue (TTM)222.99M USD
Gross Profit78.74M USD
Net Income (TTM)49.95M USD
Revenue/Share13.61 TRY
Last Price64.85 TRY
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees904
CountryTR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-212.99
EV/Revenue4.86
P/S4.71
P/B0.64
EPS (TTM)-2.69
EPS (Forward)—
52W Range
54.8013% of range132.60
52W High132.60 TRY
52W Low54.80 TRY
Profitability
Gross Margin33.36%
Oper. Margin-14.15%
EBITDA Margin-2.28%
Profit Margin21.16%
ROE3.42%
ROA2.78%
Growth
Revenue Growth-18.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF34.51M USD
CapEx (TTM)7.90M USD
FCF Margin-6.64%
FCF Yield-1.39%
Net Debt35.04M USD
Net Debt/EBITDA-6.88
Balance Sheet
Debt/Equity0.05
Current Ratio1.47
Quick Ratio0.97
Book Value/Sh100.42 TRY
Cash/Share3.63 TRY
Dividends
Fwd Div Rate1.75 TRY
Trail. Div Rate1.49 TRY
Div. Yield2.73%
5Y Avg Yield1.59%
Payout Ratio57.45%
Ex-Div DateMay 6, 2026
Pay Date—
Splits
Last Split1.25:1
Split DateNov 4, 2016
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.685.26M
Float151.11M
Insiders77.95%
Institutions1.37%
Technical
SMA 5070.22 (-7.6%)
SMA 20089.94 (-27.9%)
Beta0.28
S&P 52W Chg14.58%
Avg Vol (30d)6.01M
Avg Vol (10d)6.36M
Technical Indicators
RSI (14)46.3
MACD-2.0693
MACD Signal-2.3928
MACD Hist.+0.3234
BB Upper74.71 TRY
BB Middle65.66 TRY
BB Lower56.60 TRY
BB Width27.59%
ATR (14)3.725 TRY
Vol Ratio (20d)0.50x